Comprehensive Biomaterials 2011
DOI: 10.1016/b978-0-08-055294-1.00150-1
|View full text |Cite
|
Sign up to set email alerts
|

Delivery of Nucleic Acids and Gene Delivery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
10
0

Year Published

2014
2014
2019
2019

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 465 publications
(331 reference statements)
0
10
0
Order By: Relevance
“…The polymers can be further functionalized with target‐specific sequences for cytosolic or nuclear delivery. Moreover, in contrast to viral systems, non‐viral polymers are capable of delivering different types of nucleic acids such as pDNA, siRNA, and miRNA …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The polymers can be further functionalized with target‐specific sequences for cytosolic or nuclear delivery. Moreover, in contrast to viral systems, non‐viral polymers are capable of delivering different types of nucleic acids such as pDNA, siRNA, and miRNA …”
Section: Discussionmentioning
confidence: 99%
“…Moreover, in contrast to viral systems, non-viral polymers are capable of delivering different types of nucleic acids such as pDNA, siRNA, and miRNA. 28 In our design, we took advantage of the cationic nature of the lysine groups adjacent to the spider silk domain together with the hMSCs receptor-specific targeting capabilities of the HAB peptide to improve gene delivery towards hMSCs. It was recently demonstrated by Santos and coworkers that the HAB peptide can be specifically recognized by hMSCs.…”
Section: Discussionmentioning
confidence: 99%
“…Selected examples of viral and non-viral delivery systems that have been explored to deliver therapeutic miRNAs and siRNAs both in vivo and in vitro are summarized in Table 1 and Table 2, respectively. For a better understanding of the nucleic acids and gene delivery, please refer to the chapter summarized by Akita et al (2011) The first clinical trial of a miRNA therapy began in 2013, with the second one starting in early 2015. In contrast, the first clinical trial of a siRNA therapeutic was initiated in 2004 (Ozcan et al, 2015).…”
Section: Summary Of Delivery Systems and Clinical Status In Small Nonmentioning
confidence: 99%
“…A highly readable accounts of the topic are available (Kaneda 2001;Lechardeur and Lukacs 2002;Wiethoff and Middaugh 2003;Read et al 2005;Oupický 2005;Kabanov 2006;Wang et al 2012;Nguyen and Szoka 2012;Kamimura et al 2012). Various biological barriers for gene carriers were reviewed also by Akita et al (2011). Excess of positive charges allows electrostatic interactions with negatively charged surfaces of the target cells.…”
Section: Introductionmentioning
confidence: 98%
“…These genosomes are formed through compaction of DNA and charge neutralization and aggregation of macromolecular complexes, leading to formation of multilamellar structures (Zuidam et al 1999;Yan et al 2012). Various types of therapeutic single stranded, double stranded and hybrid nucleic acids have been designed for therapeutic gene delivery, such as plasmid DNA, oligodeoxyribonucleotides, small interference RNA (siRNA) and micro RNA (miRNA) (Akita et al 2011). Whatever nucleic acid chain topology is used (Dhanoya et al 2011), these macromolecular therapeutic assemblies should reach either the cytosol or the nucleus of target cells before successful transgene expression.…”
Section: Introductionmentioning
confidence: 99%